
CHD Stock Forecast & Price Target
CHD Analyst Ratings
Bulls say
Church & Dwight Co is viewed positively because its portfolio is anchored by powerful, category-leading brands—Arm & Hammer, TheraBreath, Hero, Batiste, OxiClean and Touchland—that together drive roughly 70% of sales and profits while supporting recurring volume growth, shelf-space gains, and strong innovation-led share expansion. Recent results reinforce that thesis: 3Q organic growth was 5.1% versus 3% guidance, with 4.6% volume growth, while management still sees gross margin expansion into 2027 through productivity, favorable mix, and operating leverage despite higher commodity and transportation costs. The business also has optionality from M&A and capital allocation, with leverage around 1.5x and a long runway in international markets, where only about 18% of sales currently come from outside the U.S.
Bears say
Church & Dwight Co is facing a weaker fundamental setup as consumer weakness has slowed growth below historical rates and management now expects Touchland to be flat in 2026, a sharp deterioration from the high teens growth expected at Investor Day. Competitive pressure, private-label threats, and a highly promotional environment could further erode share, while the company’s heavy dependence on the U.S. market limits exposure to higher-growth international opportunities. Although the business has a strong acquisition record, execution risk, volatile input costs, and a downside case implying only ~1.2% top-line CAGR and peak margins near 19% through 2034 support a negative outlook.
This aggregate rating is based on analysts' research of Church & Dwight and is not a guaranteed prediction by Public.com or investment advice.
CHD Analyst Forecast & Price Prediction
Start investing in CHD
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Church & Dwight (CHD) Forecast
CHD Analyst Forecast & Price Prediction
Start investing in CHD
Order type
Buy in
Order amount
Est. shares
0 shares